Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells.
about
The dual role of complement in cancer and its implication in anti-tumor therapyMonoclonal antibodies for the treatment of cancerSilencing of human phosphatidylethanolamine-binding protein 4 enhances rituximab-induced death and chemosensitization in B-cell lymphomaNisin ZP, a Bacteriocin and Food Preservative, Inhibits Head and Neck Cancer Tumorigenesis and Prolongs Survival.Transient removal of CD46 is safe and increases B-cell depletion by rituximab in CD46 transgenic mice and macaques.Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis.Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.Human and Epstein-Barr Virus miRNA Profiling as Predictive Biomarkers for Endemic Burkitt Lymphoma.Rapid degradation of the complement regulator, CD59, by a novel inhibitorIntracellular antigens as targets for antibody based immunotherapy of malignant diseases.rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia.Removal of the tag from His-tagged ILYd4, a human CD59 inhibitor, significantly improves its physical properties and its activity.CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma.Identification of a novel short peptide seal specific to CD59 and its effect on HeLa cell growth and apoptosis.
P2860
Q26738682-6E588F28-5A83-4C33-A0B6-77DCFB09DF98Q27025966-FB7E48B1-B3FC-4B08-AB4A-444D3401DA4FQ28486745-FCAC2786-6CF5-418C-9412-F8826ACC8D0AQ35680064-F6E4E713-2D24-4E6A-AECF-5E2B8EA75BA6Q36673736-758D1C75-0DD6-4195-82A2-0DBB2D3C77CAQ36754719-89C142AB-09D0-47CE-ADFC-E65452A5AAB5Q36797398-9BB3300E-8074-4335-8780-78F83865DFE1Q37723512-CDCB2DE3-EB65-4800-9BB6-406BFE82003CQ37727650-14965CD1-E138-4E9C-A042-C47076979928Q38644355-CBCA6371-2836-49CA-8507-ECB74DC3B1F6Q39473725-06670EE6-3728-46C1-BB06-0963840ABE74Q43084911-3AF85AB3-4CBC-4F94-8B35-086B5318C8D6Q47125786-41DBFFFD-2FEE-40A3-8670-58BC74266E7DQ51757125-6E719A75-1FD6-42C9-A2E5-DD812CEE2E2E
P2860
Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Application of a novel inhibit ...... ent cytolysis on cancer cells.
@en
Application of a novel inhibit ...... ent cytolysis on cancer cells.
@nl
type
label
Application of a novel inhibit ...... ent cytolysis on cancer cells.
@en
Application of a novel inhibit ...... ent cytolysis on cancer cells.
@nl
prefLabel
Application of a novel inhibit ...... ent cytolysis on cancer cells.
@en
Application of a novel inhibit ...... ent cytolysis on cancer cells.
@nl
P2093
P2860
P356
P1476
Application of a novel inhibit ...... ent cytolysis on cancer cells.
@en
P2093
Jingnan Shen
Xiaowen Ge
Xuebin Qin
P2860
P2888
P304
P356
10.1038/CMI.2010.35
P50
P577
2011-01-24T00:00:00Z